230 related articles for article (PubMed ID: 37578377)
1. Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma.
Seyedin R; Snider JT; Rajagopalan K; Wade SW; Gergis U
Future Oncol; 2023 Jul; 19(22):1535-1547. PubMed ID: 37578377
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
3. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
Keating SJ; Gu T; Jun MP; McBride A
Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
[TBL] [Abstract][Full Text] [Related]
4. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Lyman GH; Nguyen A; Snyder S; Gitlin M; Chung KC
JAMA Netw Open; 2020 Apr; 3(4):e202072. PubMed ID: 32250433
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
7. Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma.
Jalbert JJ; Wu N; Chen CI; Ambati S; Ge W; Arnason JE
Adv Ther; 2022 Jun; 39(6):2630-2640. PubMed ID: 35397110
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
Medina I; Carpio C; Ruiz-Camps I; Albasanz-Puig A; Lopez-Godino O; Esperalba J; Beas F; Sanchez-Salinas M; Iacoboni G; Barba P
Immunotherapy; 2023 Nov; 15(16):1369-1374. PubMed ID: 37718888
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
12. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V
Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192
[TBL] [Abstract][Full Text] [Related]
13. Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center.
Chacim S; Monjardino T; Cunha JL; Medeiros P; Redondo P; Bento MJ; Mariz JM
PLoS One; 2022; 17(12):e0278950. PubMed ID: 36490296
[TBL] [Abstract][Full Text] [Related]
14. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
16. Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy.
Ababneh HS; Ng AK; Frigault MJ; Abramson JS; Johnson PC; Jacobson CA; Patel CG
Haematologica; 2023 Nov; 108(11):2972-2981. PubMed ID: 37317884
[TBL] [Abstract][Full Text] [Related]
17. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study.
Yuen C; Rezania K; Kelly T; Bishop MR
Immunotherapy; 2021 Oct; 13(15):1261-1269. PubMed ID: 34558978
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.
Mu J; Deng H; Lyu C; Yuan J; Li Q; Wang J; Jiang Y; Deng Q; Shen J
Hematol Oncol; 2023 Apr; 41(2):275-284. PubMed ID: 35195933
[TBL] [Abstract][Full Text] [Related]
20. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Iacoboni G; Navarro V; Martín-López AÁ; Rejeski K; Kwon M; Jalowiec KA; Amat P; Reguera-Ortega JL; Gallur L; Blumenberg V; Gutiérrez-Herrero S; Roddie C; Benzaquén A; Delgado-Serrano J; Sánchez-Salinas MA; Bailén R; Carpio C; López-Corral L; Hernani R; Bastos M; O'Reilly M; Martín-Martín L; Subklewe M; Barba P
J Clin Oncol; 2024 Jan; 42(2):205-217. PubMed ID: 37874957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
